Inhibition of the biosynthesis of prostaglandin E2 by low-dose aspirin: Implications for adenocarcinoma metastasis

Cancer Prevention Research

Volumn 9, Issue 11, 2016, Pages 855-865

  Boutaud, Olivier ^a   Sosa, I Romina ^b,c   Amin, Taneem ^b   Oram, Denise ^b   Adler, David ^b   Hwang, Hyun S ^b   Crews, Brenda C ^a   Milne, Ginger ^b   Harris, Bradford K ^d   Hoeksema, Megan ^d   Knollmann, Bjorn C ^b   Lammers, Philip E ^d,e   Marnett, Lawrence J ^a   Massion, Pierre P ^d   Oates, John A ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d VANDERBILT INGRAM CANCER CENTER   (United States)

^e MEHARRY MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; PROSTAGLANDIN E2; THROMBOXANE A2; THROMBOXANE B2; PROSTAGLANDIN SYNTHASE INHIBITOR;

ADENOCARCINOMA CELL LINE; ADULT; ARTICLE; COLON ADENOCARCINOMA; DRUG BINDING SITE; DRUG EFFICACY; DRUG TRANSPORT; ENZYME ACTIVE SITE; ENZYME INHIBITION; EPITHELIAL MESENCHYMAL TRANSITION; EVENING DOSAGE; FATTY ACID BLOOD LEVEL; FEMALE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HYDROPHOBICITY; IC50; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR TRANSPORT; LOW DRUG DOSE; LUNG ADENOCARCINOMA; MALE; METASTASIS INHIBITION; NORMAL HUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS INHIBITION; PROTEIN EXPRESSION; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; UPREGULATION; URINARY EXCRETION; ADENOCARCINOMA; BIOSYNTHESIS; DRUG EFFECTS; METABOLISM; PATHOLOGY; TUMOR CELL LINE; TUMOR INVASION;

ADENOCARCINOMA; ADULT; ASPIRIN; CELL LINE, TUMOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; DINOPROSTONE; FEMALE; HUMANS; MALE; NEOPLASM INVASIVENESS;

EID: 84994765311     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-16-0094     Document Type: Article

References (73)

1. Chan AT, Giovannucci EL, Meyerhardt JA, Schernhammer ES, Curhan GC, Fuchs CS. Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA 2005; 294:914-23.
2. Chan AT, Giovannucci EL, Schernhammer ES, Colditz GA, Hunter DJ, Willett WC, et al. A prospective study of aspirin use and the risk for colorectal adenoma. Ann Intern Med 2004; 140:157-66.
3. Burn J, Mathers J, Bishop DT. Lynch syndrome: History, causes, diagnosis, treatment and prevention (CAPP2 trial). Dig Dis 2012; 30 Suppl 2:39-47.
4. Cuzick J, Otto F, Baron JA, Brown PH, Burn J, Greenwald P, et al. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: An international consensus statement. Lancet Oncol 2009; 10:501-7.
5. Schreinemachers DM, Everson RB. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 1994; 5:138-46.
6. Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: Analysis of individual patient data from randomised trials. Lancet 2011; 377:31-41.
7. Rothwell PM, Wilson M, Price JF, Belch JF, Meade TW, Mehta Z. Effect of daily aspirin on risk of cancer metastasis: A study of incident cancers during randomised controlled trials. Lancet 2012; 379:1591-601.
8. Rothwell PM, Price JF, Fowkes FG, Zanchetti A, Roncaglioni MC, Tognoni G, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: Analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 2012; 379:1602-12.
9. Menter DG, Tucker SC, Kopetz S, Sood AK, Crissman JD, Honn KV. Platelets and cancer: A casual or causal relationship: revisited. Cancer Metastasis Rev 2014; 33:231-69.
10. Gay LJ, Felding-Habermann B. Contribution of platelets to tumour metastasis. Nat Rev Cancer 2011; 11:123-34.
11. Gong L, Mi HJ, Zhu H, Zhou X, Yang H. P-selectin-mediated platelet activation promotes adhesion of non-small cell lung carcinoma cells on vascular endothelial cells under flow. Mol Med Rep 2012; 5:935-42.
12. Varki A, Varki NM, Borsig L. Molecular basis of metastasis. N Engl J Med 2009; 360:1678-9; author reply 9-80.
13. Coupland LA, Chong BH, Parish CR. Platelets and P-selectin control tumor cell metastasis in an organ-specific manner and independently of NK cells. Cancer Res 2012; 72:4662-71.
14. Warren BA, Vales O. The adhesion of thromboplastic tumour emboli to vessel walls in vivo. Br J Exp Pathol 1972; 53:301-13.
15. Erpenbeck L, Schon MP. Deadly allies: The fatal interplay between platelets and metastasizing cancer cells. Blood 2010; 115:3427-36.
16. Guillem-Llobat P, Dovizio M, Bruno A, Ricciotti E, Cufino V, Sacco A, et al. Aspirin prevents colorectal cancer metastasis in mice by splitting the crosstalk between platelets and tumor cells. Oncotarget 2016 Apr 8. [Epub ahead of print].
17. Riedl K, Krysan K, Pold M, Dalwadi H, Heuze-Vourc'h N, Dohadwala M, et al. Multifaceted roles of cyclooxygenase-2 in lung cancer. Drug Resist Updat 2004; 7:169-84.
18. Wang D, Dubois RN. Eicosanoids and cancer. Nat Rev Cancer 2010; 10: 181-93.
19. Howe LR, Subbaramaiah K, Patel J, Masferrer JL, Deora A, Hudis C, et al. Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer. Cancer Res 2002; 62:5405-7.
20. Labelle M, Begum S, Hynes RO. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell 2011; 20:576-90.
21. Wang D, Wang H, Brown J, Daikoku T, Ning W, Shi Q, et al. CXCL1 induced by prostagland in E2 promotesangiogenesisincolorectal cancer. JExp Med 2006; 203:941-51.
22. Sonoshita M, Takaku K, Sasaki N, Sugimoto Y, Ushikubi F, Narumiya S, et al. Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc(Delta 716) knockout mice. Nat Med 2001; 7:1048-51.
23. Dohadwala M, Batra RK, Luo J, Lin Y, Krysan K, Pold M, et al. Autocrine/ paracrine prostaglandin E2 production by non-small cell lung cancer cells regulates matrix metalloproteinase-2 and CD44 in cyclooxygenase-2-dependent invasion. J Biol Chem 2002; 277:50828-33.
24. Sharma S, Stolina M, Yang SC, Baratelli F, Lin JF, Atianzar K, et al. Tumor cyclooxygenase 2-dependent suppression of dendritic cell function. Clin Cancer Res 2003; 9:961-8.
25. Stolina M, Sharma S, Lin Y, Dohadwala M, Gardner B, Luo J, et al. Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J Immunol 2000; 164:361-70.
26. Yang L, Yamagata N, Yadav R, Brandon S, Courtney RL, Morrow JD, et al. Cancer-associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor. J Clin Invest 2003; 111: 727-35.
27. Yao C, Sakata D, Esaki Y, Li Y, Matsuoka T, Kuroiwa K, et al. Prostaglandin E2-EP4 signaling promotes immune inflammation through Th1 cell differentiation and Th17 cell expansion. Nat Med 2009; 15:633-40.
28. Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 1982; 69:1366-72.
29. Pedersen AK, FitzGerald GA. Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. N Engl J Med 1984; 311:1206-11.
30. Majerus PW, Stanford N. Comparative effects of aspirin and diflunisal on prostaglandin synthetase from human platelets and sheep seminal vesicles. Br J Clin Pharmacol 1977; 4 Suppl 1:15S-8S.
31. Bala M, Chin CN, Logan AT, Amin T, Marnett LJ, Boutaud O, et al. Acetylation of prostaglandin H2 synthases by aspirin is inhibited by redox cycling of the peroxidase. Biochem Pharmacol 2008; 75:1472-81.
32. Chowdhury I, Mo Y, Gao L, Kazi A, Fisher AB, Feinstein SI. Oxidant stress stimulates expression of the human peroxiredoxin 6 gene by a transcriptional mechanism involving an antioxidant response element. Free Radic Biol Med 2009; 46:146-53.
33. Lehtonen ST, Svensk AM, Soini Y, Paakko P, Hirvikoski P, Kang SW, et al. Peroxiredoxins, a novel protein family in lung cancer. Int J Cancer 2004; 111:514-21.
34. Kinnula VL, Lehtonen S, Kaarteenaho-Wiik R, Lakari E, Paakko P, Kang SW, et al. Cell specific expression of peroxiredoxins in human lung and pulmonary sarcoidosis. Thorax 2002; 57:157-64.
35. Soini Y, Kahlos K, Napankangas U, Kaarteenaho-Wiik R, Saily M, Koistinen P, et al. Widespread expression of thioredoxin and thioredoxin reductase in non-small cell lung carcinoma. Clin Cancer Res 2001; 7:1750-7.
36. Chu FF, Esworthy RS. The expression of an intestinal form of glutathione peroxidase (GSHPx-GI)inrat intestinalepithelium. Arch Biochem Biophys 1995; 323:288-94.
37. Rozell B, Hansson HA, Luthman M, Holmgren A. Immunohistochemical localization of thioredoxin and thioredoxin reductase in adult rats. Eur J Cell Biol 1985; 38:79-86.
38. Zhang B, Su YP, Ai GP, Liu XH, Wang FC, Cheng TM. Differentially expressed proteins of gamma-ray irradiated mouse intestinal epithelial cells bytwo-dimensional electrophoresis and MALDI-TOF mass spectrometry. World J Gastroenterol 2003; 9:2726-31.
39. Dovizio M, Maier TJ, Alberti S, Di Francesco L, Marcantoni E, Munch G, et al. Pharmacological inhibition of platelet-tumor cell cross-talk prevents platelet-induced overexpression of cyclooxygenase-2 in HT29 human colon carcinoma cells. Mol Pharmacol 2013; 84:25-40.
40. Boutaud O, Aronoff DM, Richardson JH, Marnett LJ, Oates JA. Determinants of the cellular specificity of acetaminophen as an inhibitor of prostaglandin H2 synthases. Proc Natl Acad Sci U S A 2002; 99:7130-5.
41. Fine KM, Ashbrook PC, Brigden LP, Maldonado JE, Didishelm P. Gelfiltered human platelets. Ultrastructure, function, and role of proteins in inhibition of aggregation by aspirin. Am J Pathol 1976; 84:11-24.
42. Boutaud O, Brame CJ, Chaurand P, Li J, Rowlinson SW, Crews BC, et al. Characterization of the lysyl adducts of prostaglandin H-synthases that are derived from oxygenation of arachidonic acid. Biochemistry 2001; 40: 6948-55.
43. Roberts LJ 2nd, Lewis RA, Oates JA, Austen KF. Prostaglandin thromboxane, and 12-hydroxy-5,8,10,14-eicosatetraenoic acid production by ion-ophore-stimulated rat serosal mast cells. Biochim Biophys Acta 1979; 575: 185-92.
44. Murphey LJ, Williams MK, Sanchez SC, Byrne LM, Csiki I, Oates JA, et al. Quantification of the major urinary metabolite of PGE2 by a liquid chromatographic/mass spectrometric assay: Determination of cyclooxy-genase-specific PGE2 synthesis in healthy humans and those with lung cancer. Anal Biochem 2004; 334:266-75.
45. Daniel VC, Minton TA, Brown NJ, Nadeau JH, Morrow JD. Simplified assay for the quantification of 2,3-dinor-6-keto-prostaglandin F1 alpha by gas chromatography-mass spectrometry. J Chromatogr B Biomed Appl 1994; 653:117-22.
46. Hamberg M, Samuelsson B. Onthe metabolism of prostag landins E1 and E 2 in man. J Biol Chem 1971; 246:6713-21.
47. Adler DH, Cogan JD, Phillips JA 3rd, Schnetz-Boutaud N, Milne GL, Iverson T, et al. Inherited human cPLA(2alpha) deficiency is associated with impaired eicosanoid biosynthesis, small intestinal ulceration, and platelet dysfunction. J Clin Invest 2008; 118:2121-31.
48. Roberts LJ 2nd, Sweetman BJ, Oates JA. Metabolism of thromboxane B2 in man. Identification of twenty urinary metabolites. J Biol Chem 1981; 256: 8384-93.
49. Uddin MJ, Crews BC, Blobaum AL, Kingsley PJ, Gorden DL, McIntyre JO, et al. Selective visualization of cyclooxygenase-2 in inflammation and cancer by targeted fluorescent imaging agents. Cancer Res 2010; 70: 3618-27.
50. Saunders MA, Belvisi MG, Cirino G, Barnes PJ, Warner TD, Mitchell JA. Mechanisms of prostaglandin E2 release by intact cells expressing cyclooxygenase-2: evidence for a two-component' model. J Pharmacol Exp Ther 1999; 288:1101-6.
51. Heasley LE, Thaler S, Nicks M, Price B, Skorecki K, Nemenoff RA. Induction of cytosolic phospholipase A2 by oncogenic Ras in human non-small cell lung cancer. J Biol Chem 1997; 272:14501-4.
52. Leslie CC Cytosolic phospholipase A(2): Physiological function and role in disease. J Lipid Res 2015; 56:1386-402.
53. Schievella AR, Regier MK, Smith WL, Lin LL. Calcium-mediated translocation of cytosolic phospholipase A2 to the nuclear envelope and endo-plasmic reticulum. J Biol Chem 1995; 270:30749-54.
54. Kamei D, Murakami M, Sasaki Y, Nakatani Y, Majima M, Ishikawa Y, et al. Microsomal prostaglandin E synthase-1 in both cancer cells and hosts contributes to tumour growth, invasion and metastasis. Biochem J 2009; 425:361-71.
55. Krysan K, Reckamp KL, Sharma S, Dubinett SM. Thepotential andrationale for COX-2 inhibitors in lung cancer. Anticancer Agents Med Chem 2006; 6:209-20.
56. Backhus LM, Sievers E, Lin GY, Castanos R, Bart RD, Starnes VA, et al. Perioperative cyclooxygenase 2 inhibition to reduce tumor cell adhesion and metastatic potential of circulating tumor cells in non-small cell lung cancer. J Thorac Cardiovasc Surg 2006; 132:297-303.
57. Chen WS, Wei SJ, Liu JM, Hsiao M, Kou-Lin J, Yang WK. Tumor invasiveness and liver metastasis of colon cancer cells correlated with cyclooxygenase-2 (COX-2) expression and inhibited by a COX-2-selective inhibitor, etodo-lac. Int J Cancer 2001; 91:894-9.
58. Bartolazzi A, Peach R, Aruffo A, Stamenkovic I. Interaction between CD44 and hyaluronate is directly implicated in the regulation of tumor development. J Exp Med 1994; 180:53-66.
59. Dohadwala M, Luo J, Zhu L, Lin Y, Dougherty GJ, Sharma S, et al. Non-small cell lung cancer cyclooxygenase-2-dependent invasion is mediated by CD44. J Biol Chem 2001; 276:20809-12.
60. Adhim Z, Matsuoka T, Bito T, Shigemura K, Lee KM, Kawabata M, et al. In vitro and in vivo inhibitory effect of three Cox-2 inhibitors and epithelial-to-mesenchymal transition in human bladder cancer cell lines. Br J Cancer 2011; 105:393-402.
61. Itatsu K, Sasaki M, Yamaguchi J, Ohira S, Ishikawa A, Ikeda H, et al. Cyclooxygenase-2 is involved in the up-regulation of matrix metallopro-teinase-9 in cholangiocarcinoma induced by tumor necrosis factor-alpha. Am J Pathol 2009; 174:829-41.
62. Yang SF, Chen MK, Hsieh YS, Chung TT, Hsieh YH, Lin CW, et al. Prostaglandin E2/EP1 signaling pathway enhances intercellular adhesion molecule 1 (ICAM-1) expression and cell motility in oral cancer cells. J Biol Chem 2010; 285:29808-16.
63. Jones MK, Wang H, Peskar BM, Levin E, Itani RM, Sarfeh IJ, et al. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: Insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med 1999; 5:1418-23.
64. Kalinski P. Regulation of immune responses by prostaglandin E2. J Immunol 2012; 188:21-8.
65. Nakao S, Kuwano T, Tsutsumi-Miyahara C, Ueda S, Kimura YN, Hamano S, et al. Infiltration of COX-2-expressing macrophages is a prerequisite for IL-1 beta-induced neovascularization and tumor growth. J Clin Invest 2005; 115:2979-91.
66. Lee JM, Yanagawa J, Peebles KA, Sharma S, Mao JT, Dubinett SM. Inflammation in lung carcinogenesis: New targets for lung cancer chemoprevention and treatment. Crit Rev Oncol Hematol 2008; 66:208-17.
67. FitzGerald GA, Oates JA, Hawiger J, Maas RL, Roberts LJ 2nd, Lawson JA, et al. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest 1983; 71:676-88.
68. Leadbeater PD, Kirkby NS, Thomas S, Dhanji AR, Tucker AT, Milne GL, et al. Aspirin has little additional anti-platelet effect in healthy volunteers receiving prasugrel. J Thromb Haemost 2011; 9:2050-6.
69. Holinstat M, Boutaud O, Apopa PL, Vesci J, Bala M, Oates JA, et al. Protease-activated receptor signaling in platelets activates cytosolic phospholipase A2alpha differently for cyclooxygenase-1 and 12-lipoxygenase catalysis. Arterioscler Thromb Vasc Biol 2011; 31:435-42.
70. Rioux N, Castonguay A. Prevention of NNK-induced lung tumorigenesis in A/J mice by acetylsalicylic acid and NS-398. Cancer Res 1998; 58:5354-60.
71. Gong L, Cai Y, Zhou X, Yang H. Activated platelets interact with lung cancer cells through P-selectin glycoprotein ligand-1. Pathol Oncol Res 2012; 18: 989-96.
72. Kim YJ, Borsig L, Varki NM, Varki A. P-selectin deficiency attenuates tumor growth and metastasis. Proc Natl Acad Sci U S A 1998; 95:9325-30.
73. Park MK, Choi JK, Kim HJ, Nakahata N, Lim KM, Kim SY, et al. Novel inhibitory effects of cardamonin on thromboxane A2-induced scratching response: Blocking of Gh/transglutaminase-2 binding to thromboxane A2 receptor. Pharmacol Biochem Behav 2014; 126:131-5.